Caribou Biosciences has initiated a $100 million underwritten public offering of shares, with an option for underwriters to purchase an additional $15 million of shares. The company plans to offer all the shares in the proposed offering.
- Genome-editing biopharmaceutical company Caribou Biosciences (NASDAQ:CRBU) said on Thursday that it has commenced a $100M underwritten public offering of shares.
- The company intends to grant the underwriters a 30-day option to purchase up to an additional $15M of shares at the public offering price.
- The company will offer all the shares in the proposed offering.
Source: SeekingAlpha